ScreenerHero

HOWL Werewolf Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · werewolftx.com
0.9201USD-0.01%Mkt Cap: 44.72M $P/E: —

Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap44.72M USD
Enterprise Value22.73M USD
Revenue (TTM)21.00M USD
Gross Profit-5.18M USD
Net Income (TTM)-60.82M USD
Revenue/Share0.44 USD
Last Price0.9201 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees39
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.56
PEG—
EV/EBITDA-1.04
EV/Revenue1.08
P/S2.13
P/B2.75
EPS (TTM)-0.73
EPS (Forward)-0.59
52W Range
0.270031% of range2.380
52W High2.380 USD
52W Low0.2700 USD
Profitability
Gross Margin-24.69%
Oper. Margin40.65%
EBITDA Margin-104.39%
Profit Margin-164.82%
ROE-245.20%
ROA-87.64%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-60.29M USD
CapEx (TTM)—
FCF Margin-58.26%
FCF Yield-27.36%
Net Debt-21.99M USD
Net Debt/EBITDA1.00
Balance Sheet
Debt/Equity1.52
Current Ratio2.91
Quick Ratio2.80
Book Value/Sh0.34 USD
Cash/Share0.45 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)7.000 USD
Upside (mean)+660.8%
Target Range4.000 USD – 10.00 USD
4.000+660.8% to mean10.00
# Analysts3
Ownership
Shares Out.48.60M
Float45.38M
Insiders6.62%
Institutions39.10%
Short Interest
Short Ratio0.1d
Short % Float4.24%
Short % Out.3.51%
Shares Short1.71M
Short (prev mo.)1.07M
Technical
SMA 500.7449 (+23.5%)
SMA 2000.6492 (+41.7%)
Beta0.51
S&P 52W Chg16.45%
Avg Vol (30d)11.11M
Avg Vol (10d)487.93K
Technical Indicators
RSI (14)57.5
MACD0.0481
MACD Signal0.0719
MACD Hist.-0.0238
BB Upper1.016 USD
BB Middle0.9526 USD
BB Lower0.8888 USD
BB Width13.39%
ATR (14)0.0492 USD
Vol Ratio (20d)0.60x